Nigel J Gooderham

Dr. Nigel J Gooderham


Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2003 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
CSChristoph Sachse
Christoph Sachse
UBUpinder Bhambra
Upinder Bhambra
GSGillian Smith
Gillian Smith
TLTracy J. Lightfoot
Tracy J. Lightfoot
JBJennifer H. Barrett
Jennifer H. Barrett
NGNigel J Gooderham
Nigel J Gooderham
Aims  Several single nucleotide polymorphisms (SNPs) of the cytochrome P450 enzyme 1A2 gene (CYP1A2) have been reported. Here, frequencies, linkage disequilibrium and phenotypic consequences of six SNPs are described.Methods  From genomic DNA, 114 British Caucasians (49 colorectal cancer cases and 65 controls) were genotyped for the CYP1A2 polymorphisms −3858G→A (allele CYP1A2*1C), −2464T→delT (CYP1A2*1D), −740T→G (CYP1A2*1E and *1G), −164A→C (CYP1A2*1F), 63C→G (CYP1A2*2), and 1545T→C (alleles CYP1A2*1B, *1G, *1H and *3), using polymerase chain reaction–restriction fragment length polymorphism assays. All patients and controls were phenotyped for CYP1A2 by h.p.l.c. analysis of urinary caffeine metabolites.Results  In 114 samples, the most frequent CYP1A2 SNPs were 1545T→C (38.2% of tested chromosomes), −164A→C (CYP1A2*1F, 33.3%) and −2464T→delT (CYP1A2*1D, 4.82%). The SNPs were in linkage disequilibrium: the most frequent constellations were found to be −3858G/−2464T/−740T/−164A/63C/1545T (61.8%), −3858G/−2464T/−740T/−164C/63C/1545C (33.3%), and −3858G/−2464delT/−740T/−164A/63C/1545C (3.51%), with no significant frequency differences between cases and controls. In the phenotype analysis, lower caffeine metabolic ratios were detected in cases than in controls. This was significant in smokers (n = 14, P = 0.020), and in a subgroup of 15 matched case‐control pairs (P = 0.007), but it was not significant in nonsmokers (n = 100, P = 0.39). There was no detectable association between CYP1A2 genotype and caffeine phenotype.Conclusions  (i) CYP1A2 polymorphisms are in linkage disequilibrium. Therefore, only −164A→C (CYP1A2*1F) and −2464T→delT (CYP1A2*1D) need to be analysed in the routine assessment of CYP1A2 genotype; (ii) in vivo CYP1A2 activity is lower in colorectal cancer patients than in controls, and (iii) CYP1A2 genotype had no effect on phenotype (based on the caffeine metabolite ratio). However, this remains to be confirmed in a larger study.

29 November 2010 in Cancer
Verified
Journal Article
Open access
PDF file
HAHutan Ashrafian
Hutan Ashrafian
KAKamran Ahmed
Kamran Ahmed
SRSimon P. Rowland
Simon P. Rowland
VPVanash M. Patel
Vanash M. Patel
NGNigel J Gooderham
Nigel J Gooderham
TAThanos Athanasiou
Thanos Athanasiou
The worldwide epidemic of obesity and the global incidence of cancer are both increasing. There is now epidemiological evidence to support a correlation between obesity, weight gain, and some cancers. Metabolic or bariatric surgery can provide sustained weight loss and reduced obesity‐related mortality. These procedures can also improve the metabolic profile to decrease cardiovascular risk and resolve diabetes in morbidly obese patients. The operations offer several physiological steps, the so‐called BRAVE effects: 1) bile flow alteration, 2) reduction of gastric size, 3) anatomical gut rearrangement and altered flow of nutrients, 4) vagal manipulation and 5) enteric gut hormone modulation. Metabolic operations are also associated with a significant reduction of cancer incidence and mortality. The cancer‐protective role of metabolic surgery is strongest for female obesity‐related tumors; however, the underlying mechanisms may involve both weight‐dependent and weight‐independent effects. These include the improvement of insulin resistance with attenuation of the metabolic syndrome as well as decreased oxidative stress and inflammation in addition to the beneficial modulation of sex steroids, gut hormones, cellular energetics, immune system, and adipokines. Elucidating the precise metabolic mechanisms of cancer prevention by metabolic surgery can increase our understanding of how obesity, diabetes, and metabolic syndrome are associated with cancer. It may also offer novel treatment strategies in the management of tumor generation and growth. Cancer 2011. © 2010 American Cancer Society.

3 September 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PKPiotr J. Kamola
Piotr J. Kamola
JKJeremy D. A. Kitson
Jeremy D. A. Kitson
GTGemma Turner
Gemma Turner
KMKlio Maratou
Klio Maratou
SESofie Eriksson
Sofie Eriksson
JPJoel D. Parry
Joel D. Parry
With many safety and technical limitations partly mitigated through chemical modifications, antisense oligonucleotides (ASOs) are gaining recognition as therapeutic entities. The increase in potency realized by ‘third generation chemistries’ may, however, simultaneously increase affinity to unintended targets with partial sequence complementarity. However, putative hybridization-dependent off-target effects (OTEs), a risk historically regarded as low, are not being adequately investigated. Here we show an unexpectedly high OTEs confirmation rate during screening of fully phosphorothioated (PS)-LNA gapmer ASOs designed against the BACH1 transcript. We demonstrate in vitro mRNA and protein knockdown of off-targets with a wide range of mismatch (MM) and gap patterns. Furthermore, with RNase H1 activity residing within the nucleus, hybridization predicted against intronic regions of pre-mRNAs was tested and confirmed. This dramatically increased ASO-binding landscape together with relatively high potency of such interactions translates into a considerable safety concern. We show here that with base pairing-driven target recognition it is possible to predict the putative off-targets and address the liability during lead design and optimization phases. Moreover, in silico analysis performed against both primary as well as spliced transcripts will be invaluable in elucidating the mechanism behind the hepatoxicity observed with some LNA-modified gapmers.

31 August 2011 in Journal of Proteome Research
Verified
Journal Article
Open access
WEWilliam M. B. Edmands
William M. B. Edmands
OBOlaf P. Beckonert
Olaf P. Beckonert
CSCinzia Stella
Cinzia Stella
ACAlison Campbell
Alison Campbell
BLBrian G. Lake
Brian G. Lake
NGNigel J Gooderham
Nigel J Gooderham
Consumption of cruciferous vegetables (CVs) is inversely correlated to many human diseases including cancer (breast, lung, and bladder), diabetes, and cardiovascular and neurological disease. Presently, there are no readily measurable biomarkers of CV consumption and intake of CVs has relied on dietary recall. Here, biomarkers of CV intake were identified in the urine of 20 healthy Caucasian adult males using 1H NMR spectroscopy with multivariate statistical modeling. The study was separated into three phases of 14 days: a run-in period with restricted CV consumption (phase I); a high CV phase where participants consumed 250 g/day of both broccoli and Brussels sprouts (phase II); a wash-out phase with a return to restricted CV consumption (phase III). Each study participant provided a complete cumulative urine collection over 48 h at the end of each phase; a spot urine (U0), 0–10 h (U0–10), 10–24 h (U10–24), and 24–48 h (U24–48) urine samples. Urine samples obtained after consumption of CVs were differentiated from low CV diet samples by four singlet 1H NMR spectroscopic peaks, one of which was identified as S-methyl-l-cysteine sulfoxide (SMCSO) and the three other peaks were tentatively identified as other metabolites structurally related to SMCSO. These stable urinary biomarkers of CV consumption will facilitate future assessment of CVs in nutritional population screening and dietary intervention studies and may correlate to population health outcomes.

22 March 2019 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
MRMohd Badrin Hanizam Abdul Rahim
Mohd Badrin Hanizam Abdul Rahim
JCJulien Chilloux
Julien Chilloux
LGLaura Martinez Gili
Laura Martinez Gili
ANAna L. Neves
Ana L. Neves
AMAntonis Myridakis
Antonis Myridakis
MDMarc-Emmanuel Dumas
Marc-Emmanuel Dumas
The human gut is a home for more than 100 trillion bacteria, far more than all other microbial populations resident on the body’s surface. The human gut microbiome is considered as a microbial organ symbiotically operating within the host. It is a collection of different cell lineages that are capable of communicating with each other and the host and has an ability to undergo self-replication for its repair and maintenance. As the gut microbiota is involved in many host processes including growth and development, an imbalance in its ecological composition may lead to disease and dysfunction in the human. Gut microbial degradation of nutrients produces bioactive metabolites that bind target receptors, activating signalling cascades, and modulating host metabolism. This review covers current findings on the nutritional and pharmacological roles of selective gut microbial metabolites, short-chain fatty acids, methylamines and indoles, as well as discussing nutritional interventions to modulate the microbiome.

1 April 2003 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
COChristian Maih Ofner
Christian Maih Ofner
MCMichalis Panayiotou Charalambous
Michalis Panayiotou Charalambous
UBUpinder Bhambra
Upinder Bhambra
TLTracy Lightfoot
Tracy Lightfoot
GGGerd Geisslinger
Gerd Geisslinger
CGCancer Group
Cancer Group
Elevated expression of cyclooxygenase-2 (COX-2), the inducible isoform of prostaglandin H synthase, has been found in several human cancers, including colorectal cancer (CRC). This appears as a rationale for the chemopreventive effects of non-steroidal anti-inflammatory drugs in CRC. However, the reason for COX-2 overexpression is not fully understood. In cell culture experiments, COX-2 can be induced by proinflammatory cytokines, such as interleukin (IL)-1beta and IL-6. A crucial step in this signalling pathway is thought to be activation of transcription factor NF-κB. Based on these findings, we hypothesized an association between COX-2 overexpression and expression of IL-1beta, IL-6 and the NF-κB subunit p65 in human CRC. To test the hypothesis, we performed immunohistochemistry for the respective antigens on colorectal cancer specimens, obtained by surgical resections from 21 patients with CRC. Immunohistochemical results were confirmed by examination of protein levels in tissue lysates and nuclear extracts using western blotting. Non-neoplastic tissue specimens resected well outside the tumour border served as controls. COX-2 expression was found to be markedly enhanced in the neoplastic epithelium compared with controls. This was paralleled by a significantly higher expression of IL-1beta, IL-6 and p65. Serial sections revealed consistent cellular colocalizations of respective antigens in the neoplastic epithelium. Statistically, a significant correlation between expression of COX-2 and IL-1beta, IL-6 and p65 was found. Comparable results were obtained for stromal cells like macrophages and myofibroblasts. Further examination of nuclear extracts from CRC-specimens by western blotting confirmed a higher content of p65 protein compared with non-neoplastic control tissues. Therefore, our study provides evidence for an association between expression of COX-2 and IL-1beta, IL-6 and p65 in human CRC. The results are consistent with the thesis that proinflammatory cytokines such as IL-1beta and IL-6 may be accountable for the overexpression of COX-2 in CRC. Finally, the study corroborates a role for NF-κB in the control of COX-2 gene transcription in CRC. Given an antiapoptotic role for COX-2 in tumour cells, inhibition of NF-κB may offer an important strategy to interfere with the development and progression of CRC.